Thermo Fisher Scientific Buys Viral Vector Manufacturing Business From Novasep for About $880 Million
January 15 2021 - 7:11AM
Dow Jones News
By Dave Sebastian
Thermo Fisher Scientific Inc. has bought Henogen SA, Groupe
Novasep SAS' viral vector manufacturing business in Belgium, for
about 725 million euros ($879.7 million) in cash, an acquisition it
said would help its capabilities for gene vaccines and
therapies.
The business, which has about 400 employees, provides
contract-manufacturing services for vaccines and therapies to
biotechnology companies and biopharma customers. It had an
estimated 2020 revenue of EUR80 million ($97 million), the
companies said.
The business will be part of Thermo Fisher Scientific's pharma
services business under the laboratory products and services
segment, it said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
January 15, 2021 06:56 ET (11:56 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Apr 2023 to Apr 2024